Chelet Bleyl, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 811 N 900 W, Orem, UT 84057 Phone: 801-434-7600 Fax: 866-381-9205 |
Desiree Funk, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 155 N 400 W # B6, Orem, UT 84057 Phone: 801-224-1300 |
Shawn Gibbs, PA Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 155 N 400 W, B6, Orem, UT 84057 Phone: 801-224-1300 Fax: 801-225-3236 |
Kevin David Stringham, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 987 S Geneva Rd Ste 116, Orem, UT 84058 Phone: 801-863-7982 |
Maria Lynn Campbell, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 717 N 450 E, Orem, UT 84097 Phone: 801-759-2827 |
Mrs. Andrea Marie Swensen, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 987 S Geneva Rd, Hp Building, Room 116, Orem, UT 84058 Phone: 801-863-7982 |
Mr. Byron Clyde Edwards, PA-C, PH.D Physician Assistant Medicare: Medicare Enrolled Practice Location: 1385 E 750 N, Orem, UT 84097 Phone: 801-224-5200 Fax: 801-224-2667 |
Travis Lee Dimond, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 730 W 800 N, Orem, UT 84057 Phone: 801-431-0100 |
Alexis Jenson Morgan, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1975 N State St, Orem, UT 84057 Phone: 801-714-5533 |
News Archive
Chief Health Officer Charles Guest's report on the health and wellbeing of the Australian Capital Territory (ACT) population between July 2006 and June 2008 was presented in the Legislative Assembly. It showed that life expectancy rate at birth in the ACT was 80.3 years for males and 84 for women. This was despite the fact that most are overweight and only a minority eats enough fruit and vegetables.
Mammography has helped lower the death rate from breast cancer, but a new report by the Institute of Medicine says much could be done to improve breast cancer screening and save even more lives.
Colorectal cancer, one of the most commonly diagnosed cancers in the United States, is not a commonly discussed disease. Often symptomless in early stages, the cancer is more difficult to treat as it progresses, requiring chemotherapy in later stages. Researchers at the University of Notre Dame are working on a way to identify patients who would benefit from chemotherapy before the cancer progresses.
Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.
› Verified 3 days ago